glp-1 chronic kidney disease Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and RAs GLP-1s in CKD: Evidence, market

Metseras lead asset is MET-097i a potential once-monthly formulation of GLP-1RA with improved efficacy and lower GI AEs (nausea, vomiting, diarrhea) compared to on-market competitors

However, new evidence has been forthcoming in recent years to suggest that human food intake is also controlled by other areas in the central nervous system, such as subcortical and cortical areas

Manuka honey was the most effective, perturbing intracellular ROS and calcium signaling as well as inducing apoptosis

75 WeisM.MorgensternR.CotgreaveI

Store in a cool, dry place away from light, at a temperature of 0-25C, out of reach of small children

Would love to hear how clinicians amd marketers are viewing this evolving DPP 4 landscape